Dr. Goy Discusses Single-Agent Ibrutinib in MCL

Andre Goy, MD
Published: Monday, Dec 11, 2017



Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

A long-term follow-up of single-agent ibrutinib was presented at the 2017 ASH Annual Meeting. Goy reports that the complete response rate was up to 26%. Additionally, at 3 years, one-quarter of patients still had not progressed.

However, work still needs to be done to determine which patients would benefit best from ibrutinib, Goy adds.
 


Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

A long-term follow-up of single-agent ibrutinib was presented at the 2017 ASH Annual Meeting. Goy reports that the complete response rate was up to 26%. Additionally, at 3 years, one-quarter of patients still had not progressed.

However, work still needs to be done to determine which patients would benefit best from ibrutinib, Goy adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x